Editas Medicine, Inc. (LON: 0IFK)

Market Cap	81.07M
Revenue (ttm)	46.08M
Net Income (ttm)	-157.11M
Shares Out	n/a
EPS (ttm)	-1.91
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	660
Average Volume	23,734
Open	1.410
Previous Close	1.260
Day's Range	1.410 - 1.410
52-Week Range	1.410 - 11.790
Beta	n/a
RSI	33.49
Earnings Date	Feb 21, 2025

About Editas Medicine

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumor...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2013
• Employees: 265
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0IFK

Financial Performance

In 2023, Editas Medicine's revenue was $78.12 million, an increase of 296.32% compared to the previous year's $19.71 million. Losses were -$153.22 million, -30.49% less than in 2022.

Financial numbers in USD